Research

Hormonal

Peripheral GLP-1 receptor agonists (GLP-1RAs) exert brain-mediated anorectic effects primarily via access to circumventricular organs (CVOs) like the area postrema and median eminence, rather than crossing the blood-brain barrier (BBB) or blood-cerebrospinal fluid barrier (BCB).

GLP-1 medications like Semaglutide and Liraglutide reduce appetite by signaling from the gut to specific brain regions (CVOs) via the vagus nerve, rather than crossing into the brain tissue itself. This explains why they are effective for weight loss even though very little drug actually enters the cerebrospinal fluid.

GoodQualifiesHIGH confidence
Peripherally administrated GLP-1RAs may access the brain via ME and AP, as well as other selective CVOs. We hence intend to suggest that gut-produced native GLP-1 and peripherally administrated GLP-1RA as therapeutic agent do not access the brain via BCB.
Jiao Feng et al. · Journal of Translational Internal Medicine · 2025

Why this rating

The paper is a review synthesizing multiple studies, including clinical data showing minimal CSF transfer despite significant weight loss.

Source

Current understanding and controversy on brain access of GLP-1 and GLP-1 receptor agonists

Jiao Feng et al. · Journal of Translational Internal Medicine · 2025

DOI 10.1515/jtim-2025-0026

narrative_reviewCited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →